← Leaderboards
Eva L Feldman
University Of Michigan At Ann Arbor
$26,770,746
Attributed
$57,848,399
Total exposure
25
Grants
19
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.8M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$53,419,547 · 22
ATSDR$4,428,852 · 3
By mechanism
R01$26,408,622 · 12
R24$13,121,043 · 1
DP3$5,514,789 · 1
T32$5,470,967 · 1
U01$4,728,744 · 2
U2C$1,130,085 · 1
Top collaborators
- Frank C Brosius14 shared
- Subramaniam Pennathur14 shared
- Matthias Kretzler13 shared
- Stuart A Batterman12 shared
- Stephen Goutman11 shared
- H V Jagadish10 shared
- Rodica Pop-Busui7 shared
- Nicholas M Boulis6 shared
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Subramaniam Pennathur$11,719,201
- Stuart A Batterman$13,600,215
- Frank C Brosius$16,808,691
- Matthias Kretzler$40,447,062
- Amy E. Rumora$985,566
Others in their field
Top investigators on “Pathogenesis”
- Jeffrey P Krischer · University Of South Florida$473,867,135
- Constance Ann Benson · University Of California, San Diego$309,631,408
- Daniel R Kuritzkes · Brigham And Women'S Hospital$212,627,101
- Richard K. Wilson · Washington University$203,917,615
- Michael David Hughes · Harvard University D/B/A Harvard School Of Public Health$198,007,440
- Carol Nesel · Westat$147,274,423
Research focus
PathogenesisComplications Of Diabetes MellitusMetabolicDiabetes MellitusAffectComplexBaseResponseMouse ModelTissuesPhenotypeLinkPreventNeuropathyCohortGeneticInsightBiologicalPreventionDisease ProgressionPathway InteractionsAnimalsDiagnosisGenes
Grant awards (117)
Integrating the exposome and epigenome identifies determinants of ALS risk, survival, and pathogenesis$3,133,754
R01 · FY2025 · ES · contact PI
Metabolic coupling between Schwann cells and axons is functionally distinct from myelination and is disrupted in obesity, prediabetes, and diabetes$621,686
R01 · FY2025 · DK · contact PI
RFA-TS-23-001: Establishing the Cohort for Occupational Risk and Prevention Studies for Amyotrophic Lateral Sclerosis (ALS CORPS)$500,000
R01 · FY2025 · TS
Identifying lifelong factors that impact brain health and outcomes in type 1 diabetes: The Cognition and Longitudinal Assessments of Risk Factors over 30 Years (CLARiFY) Diabetes Complications Study$442,439
R01 · FY2025 · DK · contact PI
Developing novel strategies for personalized treatment and prevention of ALS: Leveraging the global exposome, genome, epigenome, metabolome, and inflammasome with data science in a case/control cohort$719,029
R01 · FY2024 · NS · contact PI
Mapping the ALS Exposome to Gain New Insights into Disease Risk and Pathogenesis$653,107
R01 · FY2024 · ES · contact PI
Metabolic coupling between Schwann cells and axons is functionally distinct from myelination and is disrupted in obesity, prediabetes, and diabetes$605,984
R01 · FY2024 · DK · contact PI
RFA-TS-23-001: Establishing the Cohort for Occupational Risk and Prevention Studies for Amyotrophic Lateral Sclerosis (ALS CORPS)$500,000
R01 · FY2024 · TS
Identifying lifelong factors that impact brain health and outcomes in type 1 diabetes: The Cognition and Longitudinal Assessments of Risk Factors over 30 Years (CLARiFY) Diabetes Complications Study$439,740
R01 · FY2024 · DK · contact PI
Developing novel strategies for personalized treatment and prevention of ALS: Leveraging the global exposome, genome, epigenome, metabolome, and inflammasome with data science in a case/control cohort$736,527
R01 · FY2023 · NS · contact PI
Mapping the ALS Exposome to Gain New Insights into Disease Risk and Pathogenesis$653,107
R01 · FY2023 · ES · contact PI
Metabolic coupling between Schwann cells and axons is functionally distinct from myelination and is disrupted in obesity, prediabetes, and diabetes$640,503
R01 · FY2023 · DK · contact PI
Establishing the Cohort for Occupational Risk and Prevention Studies for Amyotrophic Lateral Sclerosis (ALS CORPS)$500,000
R01 · FY2023 · TS
Linking long-term air pollution exposure with inflammation, ALS risk, and disease progression$499,206
R01 · FY2023 · TS · contact PI
Identifying lifelong factors that impact brain health and outcomes in type 1 diabetes: The Cognition and Longitudinal Assessments of Risk Factors over 30 Years (CLARiFY) Diabetes Complications Study$465,106
R01 · FY2023 · DK · contact PI
Developing novel strategies for personalized treatment and prevention of ALS: Leveraging the global exposome, genome, epigenome, metabolome, and inflammasome with data science in a case/control cohort$984,329
R01 · FY2022 · NS · contact PI
Metabolic coupling between Schwann cells and axons is functionally distinct from myelination and is disrupted in obesity, prediabetes, and diabetes$663,188
R01 · FY2022 · DK · contact PI
Mapping the ALS Exposome to Gain New Insights into Disease Risk and Pathogenesis$653,107
R01 · FY2022 · ES · contact PI
Linking long-term air pollution exposure with inflammation, ALS risk, and disease progression$499,206
R01 · FY2022 · TS · contact PI
Identifying lifelong factors that impact brain health and outcomes in type 1 diabetes: The Cognition and Longitudinal Assessments of Risk Factors over 30 Years (CLARiFY) Diabetes Complications Study$467,750
R01 · FY2022 · DK · contact PI
Mapping the ALS Exposome to Gain New Insights into Disease Risk and Pathogenesis$132,550
R01 · FY2022 · ES · contact PI
Developing novel strategies for personalized treatment and prevention of ALS: Leveraging the global exposome, genome, epigenome, metabolome, and inflammasome with data science in a case/control cohort$989,984
R01 · FY2021 · NS · contact PI
Mapping the ALS Exposome to Gain New Insights into Disease Risk and Pathogenesis$653,107
R01 · FY2021 · ES · contact PI
Identifying lifelong factors that impact brain health and outcomes in type 1 diabetes: The Cognition and Longitudinal Assessments of Risk Factors over 30 Years (CLARiFY) Diabetes Complications Study$509,996
R01 · FY2021 · DK · contact PI
Linking long-term air pollution exposure with inflammation, ALS risk, and disease progression$400,440
R01 · FY2021 · TS · contact PI
Mapping the ALS Exposome to Gain New Insights into Disease Risk and Pathogenesis$132,550
R01 · FY2021 · ES · contact PI
Neural Stem Cell Transplantation: A Novel Cellular Therapy for Alzheimer's Disease$1,371,564
U01 · FY2020 · AG · contact PI
Integrated Systems Biology Approach to Diabetic Microvascular Complications$1,364,409
R24 · FY2020 · DK · contact PI
Mapping the ALS Exposome to Gain New Insights into Disease Risk and Pathogenesis$653,107
R01 · FY2020 · ES · contact PI
Metabolomic Signatures Linking ALS to Persistent Organic Pollutant Exposures$530,000
R01 · FY2020 · TS · contact PI
Targeting Inflammation with Salsalate as a Novel Therapy for Diabetic Neuropathy$471,210
R01 · FY2020 · DK · contact PI
Core E: Microvascular Complications Core$210,422
U2C · FY2020 · DK · contact PI
Integrated Systems Biology Approach to Diabetic Microvascular Complications$1,368,284
R24 · FY2019 · DK · contact PI
Neural Stem Cell Transplantation: A Novel Cellular Therapy for Alzheimer's Disease$1,032,520
U01 · FY2019 · AG · contact PI
Targeting Inflammation with Salsalate as a Novel Therapy for Diabetic Neuropathy$578,101
R01 · FY2019 · DK · contact PI
Metabolomic Signatures Linking ALS to Persistent Organic Pollutant Exposures$500,000
R01 · FY2019 · TS · contact PI
Training in Clinical and Basic Neuroscience$411,455
T32 · FY2019 · NS · contact PI
Neural Stem Cell Transplantation: A Novel Cellular Therapy for Alzheimer's Disease$390,000
U01 · FY2019 · AG · contact PI
Linking Nerve Bioenergetics with Metabolomics: New Insights into Diabetic Neuroapthy$273,000
R21 · FY2019 · NS · contact PI
Core E: Microvascular Complications Core$221,238
U2C · FY2019 · DK · contact PI
The Role of NK Cells in ALS$193,750
R21 · FY2019 · NS · contact PI
Integrated Systems Biology Approach to Diabetic Microvascular Complications$1,374,854
R24 · FY2018 · DK · contact PI
Neural Stem Cell Transplantation: A Novel Cellular Therapy for Alzheimer's Disease$687,010
U01 · FY2018 · AG · contact PI
Targeting Inflammation with Salsalate as a Novel Therapy for Diabetic Neuropathy$579,358
R01 · FY2018 · DK · contact PI
Metabolomic Signatures Linking ALS to Persistent Organic Pollutant Exposures$500,000
R01 · FY2018 · TS · contact PI
Training in Clinical and Basic Neuroscience$397,566
T32 · FY2018 · NS · contact PI
Integrated Systems Biology Approach to Diabetic Microvascular Complications$390,000
R24 · FY2018 · DK · contact PI
Core E: Microvascular Complications Core$228,961
U2C · FY2018 · DK · contact PI
The Role of NK Cells in ALS$194,687
R21 · FY2018 · NS · contact PI
Targeting Inflammation with Salsalate as a Novel Therapy for Diabetic Neuropathy$190,635
R01 · FY2018 · DK · contact PI
Linking Nerve Bioenergetics with Metabolomics: New Insights into Diabetic Neuroapthy$156,000
R21 · FY2018 · NS · contact PI
Training in Clinical and Basic Neuroscience$648
T32 · FY2018 · NS · contact PI
Integrated Systems Biology Approach to Diabetic Microvascular Complications$1,378,119
R24 · FY2017 · DK · contact PI
Targeting Inflammation with Salsalate as a Novel Therapy for Diabetic Neuropathy$588,280
R01 · FY2017 · DK · contact PI
Training in Clinical and Basic Neuroscience$373,909
T32 · FY2017 · NS · contact PI
Core E: Microvascular Complications Core$234,360
U2C · FY2017 · DK · contact PI
Integrated Systems Biology Approach to Diabetic Microvascular Complications$1,395,579
R24 · FY2016 · DK · contact PI
Targeting Inflammation with Salsalate as a Novel Therapy for Diabetic Neuropathy$594,488
R01 · FY2016 · DK · contact PI
Core E: Microvascular Complications Core$235,104
U2C · FY2016 · DK · contact PI
Training in Clinical and Basic Neuroscience$170,867
T32 · FY2016 · NS · contact PI
Training in Clinical and Basic Neuroscience$57,285
T32 · FY2016 · NS · contact PI
Phase 1b Trial of stem cells in ALS$709,886
R01 · FY2015 · NS
Training in Clinical and Basic Neuroscience$214,967
T32 · FY2015 · NS · contact PI
Training in Clinical and Basic Neuroscience$120,135
T32 · FY2015 · NS · contact PI
Phase 1b Trial of stem cells in ALS$54,673
R01 · FY2015 · NS
Phase 1b Trial of stem cells in ALS$36,505
R01 · FY2015 · NS
Integrated Systems Biology Approach to Diabetic Microvascular Complications$1,092,803
R24 · FY2014 · DK
Phase 1b Trial of stem cells in ALS$577,888
R01 · FY2014 · NS
Training in Clinical and Basic Neuroscience$428,102
T32 · FY2014 · NS · contact PI
Integrated Systems Biology Approach to Diabetic Microvascular Complications$1,117,286
R24 · FY2013 · DK
Phase 1b Trial of stem cells in ALS$562,841
R01 · FY2013 · NS
Training in Clinical and Basic Neuroscience$265,392
T32 · FY2013 · NS · contact PI
Training in Clinical and Basic Neuroscience$56,905
T32 · FY2013 · NS · contact PI
Integrated Systems Biology Approach to Diabetic Microvascular Complications$1,051,333
R24 · FY2012 · DK
Phase 1b Trial of stem cells in ALS$595,628
R01 · FY2012 · NS
Training in Clinical and Basic Neuroscience$256,048
T32 · FY2012 · NS · contact PI
Training in Clinical and Basic Neuroscience$168,046
T32 · FY2012 · NS · contact PI
Integrated Systems Biology Approach to Diabetic Microvascular Complications$65,007
R24 · FY2012 · DK
Tissue-Specific Metabolic Reprogramming in Diabetic Complications$5,514,789
DP3 · FY2011 · DK
Integrated Systems Biology Approach to Diabetic Microvascular Complications$1,045,153
R24 · FY2011 · DK
Training in Clinical and Basic Neuroscience$119,408
T32 · FY2011 · NS · contact PI
Targeting Inflammation using Salsalate in Type 1 Diabetic Neuropathy (TINSAL-T1DN$77,750
R03 · FY2011 · DK
Integrated Systems Biology Approach to Diabetic Microvascular Complications$1,014,716
R24 · FY2010 · DK
Mitochondrial SOD as a Target for Diabetic Neuropathy$287,132
U01 · FY2010 · DK · contact PI
Biomarkers in Diabetic Neuropathy$263,250
RC1 · FY2010 · NS · contact PI
Training in Clinical and Basic Neuroscience$171,251
T32 · FY2010 · NS · contact PI
Training in Clinical and Basic Neuroscience$111,918
T32 · FY2010 · NS · contact PI
Training in Clinical and Basic Neuroscience$378,627
T32 · FY2009 · NS · contact PI
Mitochondrial SOD as a Target for Diabetic Neuropathy$302,967
U01 · FY2009 · DK · contact PI
Biomarkers in Diabetic Neuropathy$255,582
RC1 · FY2009 · NS · contact PI
Mitochondrial SOD as a Target for Diabetic Neuropathy$34,898
U01 · FY2009 · DK · contact PI
2009 International Peripheral Nerve Society Meeting at Wurzburg, Germany$28,000
R13 · FY2009 · NS · contact PI
Integrated Systems Biology Approach to Diabetic Microvascular Complications$463,500
R24 · FY2008 · DK
Training in Clinical and Basic Neuroscience$315,813
T32 · FY2008 · NS · contact PI
Mitochondrial SOD as a Target for Diabetic Neuropathy$217,051
U01 · FY2008 · DK · contact PI
Training in Clinical and Basic Neuroscience$105,270
T32 · FY2008 · NS · contact PI
Training in Clinical and Basic Neuroscience$249,653
T32 · FY2007 · NS · contact PI
Mitochondrial SOD as a Target for Diabetic Neuropathy$209,460
U01 · FY2007 · DK · contact PI
OXIDATIVE STRESS & CV DENERVATION IN DIABETES: AN INTERVENTIONAL TRIAL$12,202
M01 · FY2007 · RR · contact PI
Mitochondrial SOD as a Target for Diabetic Neuropathy$196,142
U01 · FY2006 · DK · contact PI
Training in Clinical and Basic Neuroscience$150,601
T32 · FY2006 · NS · contact PI
OXIDATIVE STRESS & CV DENERVATION IN DIABETES: AN INTERVENTIONAL TRIAL$19,928
M01 · FY2006 · RR · contact PI
Training in Clinical and Basic Neuroscience$264,816
T32 · FY2005 · NS
Glucotoxicity Mediates Apoptosis in Diabetic Neuropathy$213,368
R01 · FY2005 · NS
Training in Clinical and Basic Neuroscience$51,258
T32 · FY2005 · NS
Training in Clinical and Basic Neuroscience$247,825
T32 · FY2004 · NS
Glucotoxicity Mediates Apoptosis in Diabetic Neuropathy$213,437
R01 · FY2004 · NS
Training in Clinical and Basic Neuroscience$53,126
T32 · FY2004 · NS
Training in Clinical and Basic Neuroscience$259,062
T32 · FY2003 · NS
Glucotoxicity Mediates Apoptosis in Diabetic Neuropathy$213,504
R01 · FY2003 · NS
Glucotoxicity Mediates Apoptosis in Diabetic Neuropathy$213,569
R01 · FY2002 · NS
IGFS MEDIATE MOTILITY IN HUMAN NEUROBLASTOMA CELLS$200,530
R01 · FY2002 · NS
Training in Clinical and Basic Neuroscience$71,014
T32 · FY2002 · NS
IGFS MEDIATE MOTILITY IN HUMAN NEUROBLASTOMA CELLS$194,689
R01 · FY2001 · NS
IGFS MEDIATE MOTILITY IN HUMAN NEUROBLASTOMA CELLS$1,512
R01 · FY2001 · NS
IGFS MEDIATE MOTILITY IN HUMAN NEUROBLASTOMA CELLS$189,018
R01 · FY2000 · NS
IGFS MEDIATE MOTILITY IN HUMAN NEUROBLASTOMA CELLS$50,000
R01 · FY2000 · NS